Anti-human transferrin receptor antibody and uses thereof
One embodiment of the disclosure provides an amino sequence of an anti-human transferrin receptor antibody, including: an amino sequence of a heavy chain variable region which is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.
1. An isolated anti-human transferrin receptor antibody, comprising:
a heavy chain variable region of which the amino acid sequence is represented by SEQ ID NO.: 1 or SEQ ID NO.: 2,
wherein the anti-human transferrin receptor antibody is capable of specifically binding to a human transferrin receptor.
2. The isolated anti-human transferrin receptor antibody as claimed in claim 1 , wherein the amino sequence of the heavy chain variable region represented by SEQ ID NO.: 1 is encoded by a nucleotide sequence represented by SEQ ID NO.: 3.
3. The isolated anti-human transferrin receptor antibody as claimed in claim 1 , wherein the amino sequence of the heavy chain variable region represented by SEQ ID NO.: 2 is encoded by a nucleotide sequence represented by SEQ ID NO.: 4.
4. The isolated anti-human transferrin receptor antibody as claimed in claim 1 , wherein the anti-human transferrin receptor antibody is capable of entering a cell through receptor-mediated endocytosis.
5. A fusion protein, comprising:
the isolated anti-human transferrin receptor antibody as claimed in claim 1 ; and
a fragment crystallizable region (Fc) of a human immunoglobulin G connected to the anti-human transferrin receptor antibody,
wherein the fusion protein is capable of specifically binding to a human transferrin receptor.
6. The fusion protein as claimed in claim 5 , wherein the fusion protein is bivalent.
7. The fusion protein as claimed in claim 5 , wherein the fusion protein is capable of entering a cell through receptor-mediated endocytosis.
8. An imaging agent, comprising:
the isolated anti-human transferrin receptor antibody as claimed in claim 1 ; and
a labeling material connected to the anti-human transferrin receptor antibody.
9. The imaging agent as claimed in claim 8 , wherein the labeling material comprises:
a carrier; and
a chromogenic substance or radioactive substance connected to a surface of the carrier.
10. The imaging agent as claimed in claim 9 , wherein the carrier comprises a liposome, a micelle, a bead, a nanoparticle or colloidal gold.
11. The imaging agent as claimed in claim 9 , wherein the chromogenic substance comprises a fluorescent dye, a magnetic resonance imaging (MRI) reagent or an iodine-containing imaging agent for X-ray imaging and computed tomography (CT).
12. The imaging agent as claimed in claim 9 , wherein the radioactive substance comprises Yttrium-90 (Y-90), Indium-111 (In-111) or Iodine-131 (I-131).
13. The imaging agent as claimed in claim 8 , wherein the labeling material is a chromogenic substance or radioactive substance.
14. The imaging agent as claimed in claim 13 , wherein the chromogenic substance comprises a fluorescent dye, a magnetic resonance imaging (MRI) reagent or an iodine-containing imaging agent for X-ray imaging and computed tomography (CT).
15. The imaging agent as claimed in claim 13 , wherein the radioactive substance comprises Yttrium-90, Indium-111 or Iodine-131.
16. A method for labeling or imaging a cell or tissue, comprising:
providing an imaging agent, wherein the imaging agent comprises the isolated anti-human transferrin receptor antibody as claimed in claim 1 and a labeling material connected to the anti-human transferrin receptor antibody; and
contacting the imaging agent with a cell or tissue to be labeled or imaged, wherein the antibody of the imaging agent binds to a human transferrin receptor expressed by the cell or tissue and causes the cell or tissue be labeled or imaged.
17. A pharmaceutical composition, comprising:
an effective amount of an isolated antibody comprising a heavy chain variable region, wherein an amino sequence of the heavy chain variable region comprises a sequence represented by SEQ ID NO.: 1 or SEQ ID NO.: 2, and the antibody is capable of specifically binding to a human transferrin receptor.
18. The pharmaceutical composition as claimed in claim 17 , wherein the pharmaceutical composition is used for a treatment of brain cancer, leukaemia, prostate cancer, lung cancer or breast cancer.